[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fakaYy0gxPo8L5GI-I20KUbmjrSkl4E4YxFDlSYHUbx0":8,"$fdi1rLz7BGLSsYUeScgNugI-eDRxr6hH7kpRQEFQrAhU":55,"$fsRfK87WN3DNo-0FmrTNtEuPUq3wWKv1FX_AyP6iNoug":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},65194,862794,[],"https://cdn.yishi-tong.com/console/store-1/Si4P_fC5H_NUK1-yWqxbthvHo_drnUm_.jpg","周瀚","安丘市人民医院","普外科","主治医师",425,0,"乳腺癌早期靶向治疗：懂得曲妥珠单抗的正确使用","","https://ystcdn.venuertc.com/venue/AI/5cfb19e0-52d7-432e-a30b-95701dfa955f.jpg","\u003Cdiv class=\"custom-breastca-guide\">\n  \u003Ch1 id=\"material_title\" class=\"custom-breastca-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺癌早期靶向治疗：懂得曲妥珠单抗的正确使用\u003C/h1>\n  \u003Cdiv class=\"custom-breastca-intro\">\n    \u003Cp>说起来，曲妥珠单抗（Trastuzumab）是一种非常具有代表性的靶向药物，它常被用于HER2相关乳腺癌的治疗，但具体怎么用、有哪些细节需要留意，很多人其实并不太清楚。本文会详细分解曲妥珠单抗实用指南，从药理机制、用法剂量，到相互作用、不良反应和储存办法等，全方位帮你把握7个药品使用要点，让用药更安心、更到位。\u003C/p>\n  \u003C/div>\n\n  \u003C!-- 01 曲妥珠单抗的作用机制 -->\n  \u003Csection class=\"custom-breastca-section\" style=\"background: linear-gradient(90deg, #f3f7fa 20%, #e6f1fb 100%);padding:32px 24px;border-radius:14px;margin-top:24px;\">\n    \u003Ch2 class=\"custom-breastca-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 🎯 药理机制：曲妥珠单抗怎么起作用？\u003C/h2>\n    \u003Cp>\n      曲妥珠单抗是一种单克隆抗体，属于靶向药物。\u003Cbr>\n      它的机制主要是专一性识别并结合HER2受体（人表皮生长因子受体2），从而阻断HER2介导的信号通路。这样，可以抑制异常细胞的生长增殖过程，有效地针对相关细胞进行清除。\u003Cbr>\n      正因为其特异性强，曲妥珠单抗能够较为精准地作用于靶点细胞，对于健康细胞的影响相对较小，所以在治疗过程中，通常副作用较传统化疗药物更温和。\n      \u003Cbr>\n      \u003Cspan class=\"custom-breastca-cite\">（参考：Baselga et al., Trastuzumab: mechanism of action and potential for resistance, Cancer Research, 2001）\u003C/span>\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 02 剂型规格与给药方式 -->\n  \u003Csection class=\"custom-breastca-section\" style=\"background: linear-gradient(90deg, #faf8f9 0%, #f4f4f7 80%);padding:32px 24px;border-radius:14px;margin-top:24px;\">\n    \u003Ch2 class=\"custom-breastca-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 💉 剂型和用药技巧：怎么用曲妥珠单抗？\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>给药剂型：\u003C/strong>曲妥珠单抗目前主要有两种剂型：注射用冻干粉剂（需溶解）和预混液体制剂（直接使用）。绝大多数场景为静脉注射，部分国家也有皮下注射型。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>服用方式：\u003C/strong>不能口服，需专业医护人员操作，通过静脉滴注或皮下注射完成。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>用药步骤：\u003C/strong>\n        \u003Col>\n          \u003Cli>首剂常需在医护监护下缓慢滴注，后续可适当缩短滴注时间。\u003C/li>\n          \u003Cli>建议每次注射后，现场留观至少数小时。\u003C/li>\n        \u003C/ol>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特别提醒：\u003C/strong>家庭用药及自行注射都不安全，切勿自行操作。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"custom-breastca-case\">\n      临床上使用曲妥珠单抗时，首次注射大多要求患者全程留院观察，防范输注反应。\n    \u003C/p>\n    \u003Cp>\n      \u003Cspan class=\"custom-breastca-cite\">（参考：Slamon et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer, NEJM, 2001）\u003C/span>\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 03 推荐剂量和给药间隔 -->\n  \u003Csection class=\"custom-breastca-section\" style=\"background: linear-gradient(90deg, #f5fcf7 10%, #f7f7fa 100%);padding:32px 24px;border-radius:14px;margin-top:24px;\">\n    \u003Ch2 class=\"custom-breastca-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 ⏰ 剂量与间隔：每次用多少？多久用一次？\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>静脉注射标准：\u003C/strong>\u003Cbr>\n        推荐初始剂量为8 mg/kg体重，首剂后每周一次4 mg/kg维持，或每三周一次6 mg/kg（视不同方案）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>皮下注射标准：\u003C/strong>\n        每次固定用量600 mg，皮下注射（仅限特定制剂）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>给药间隔：\u003C/strong>须严格按课程进行。推迟1~2天需重新评估后再给药，勿擅自延后或提前。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>漏用处理：\u003C/strong>忘记按时使用，应尽早补用，并回归原计划。勿在下次用药时自行加量。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确认知和遵循医嘱剂量安方案，是最大限度发挥药物效果和减少副作用的基本保障。\n    \u003C/p>\n    \u003Cp>\n      \u003Cspan class=\"custom-breastca-cite\">（参考：Herceptin（trastuzumab） prescribing information, Roche, 2024）\u003C/span>\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 04 药物相互作用清单 -->\n  \u003Csection class=\"custom-breastca-section\" style=\"background: linear-gradient(90deg, #f2fafa 30%, #e9f8f4 100%);padding:32px 24px;border-radius:14px;margin-top:24px;\">\n    \u003Ch2 class=\"custom-breastca-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 🔄 药物相互作用及联合用药注意\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>与化疗药物：\u003C/strong>常和多柔比星、紫杉类等联用，但同用时心脏毒性风险会增高，尤其要避免前后大剂量化疗交叉。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>与其他靶向药物：\u003C/strong>不同靶点的联合（如帕妥珠单抗、拉帕替尼）需按医师方案调整剂量。不可自行添加。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>常规药物：\u003C/strong>目前未发现与常见止痛、退烧或感冒药显著冲突，但如合用激素类、抗真菌/抗病毒药物，要告知医生。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>食物影响：\u003C/strong>曲妥珠单抗为注射制剂，进食本身无影响，但治疗期间饮食以清淡为宜，避免大量酒精摄入。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"custom-breastca-cite\">（参考：de Azambuja E et al., Safety and efficacy of trastuzumab, Annals of Oncology, 2014）\u003C/span>\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 05 特殊人群用药须知 -->\n  \u003Csection class=\"custom-breastca-section\" style=\"background: linear-gradient(90deg, #f6f4fa 10%, #e2eaf8 100%);padding:32px 24px;border-radius:14px;margin-top:24px;\">\n    \u003Ch2 class=\"custom-breastca-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 👵👶 特殊人群怎么用？\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>老年人：\u003C/strong>起始剂量一般不变，但更要密切监测心脏功能和肝肾指标，身体虚弱者需个体化调整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>肝肾功能不全：\u003C/strong>轻中度损伤一般不需调整剂量，重度损伤者需权衡利弊决定。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>孕妇及哺乳期：\u003C/strong>\n        动物和部分病例显示可通过胎盘或乳汁分布，可能对胎儿有风险。孕妇或计划怀孕、哺乳者应避免使用，服药后至少7个月避孕，哺乳期应暂停母乳。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>儿童：\u003C/strong>目前缺乏充分安全性和有效性数据，18岁以下不建议常规使用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      有位孕妇在不明情况下接受曲妥珠单抗，之后立即中止治疗并严格随访，未出现显著不良事件。安全起见，仍建议未完成生育者谨慎评估。\n    \u003C/p>\n    \u003Cp>\n      \u003Cspan class=\"custom-breastca-cite\">（参考：Pondé NF et al., Trastuzumab in breast cancer: a tale of two tails, Nat Rev Clin Oncol, 2019）\u003C/span>\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 06 常见不良反应与应对措施 -->\n  \u003Csection class=\"custom-breastca-section\" style=\"background: linear-gradient(90deg, #faefe6 30%, #f9fafb 100%);padding:32px 24px;border-radius:14px;margin-top:24px;\">\n    \u003Ch2 class=\"custom-breastca-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 ⚠️ 不良反应及简单处理办法\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>输注反应：\u003C/strong>首次或前几次静脉滴注易见发热、寒战、皮疹等（约15-20%）。遇发热等症状，立即停药并就医，如反应较轻可对症给予抗过敏和退烧药物。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>心脏毒性：\u003C/strong>心功能下降、心衰风险约为2-7%。高危患者（既往心脏疾病、较大剂量化疗史）需每个周期中定期做心脏超声和心电图筛查。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>其他常见反应：\u003C/strong>如腹泻、乏力、轻度肝酶升高等。通常无需特殊处理，短期自行缓解。如出现严重疲劳、黄疸等持续性体征，及时停药并联系医生。\u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"custom-breastca-cite\">（数据来源：Herceptin说明书，美国FDA，2023）\u003C/span>\n    \u003C/p>\n    \u003Cp>\n      临床案例显示：有位患者接受曲妥珠单抗周期治疗，因出现一过性腹泻及时调整饮食，未影响后续用药。\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 07 储存、运输与有效期说明 -->\n  \u003Csection class=\"custom-breastca-section\" style=\"background: linear-gradient(90deg, #e7f7f6 30%, #f4f9fa 100%);padding:32px 24px;border-radius:14px;margin-top:24px;\">\n    \u003Ch2 class=\"custom-breastca-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 🛡️ 储存方法和过期处理\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>储存要求：\u003C/strong>未开封产品建议2~8℃冷藏，避免冷冻。注射液体不可反复冷藏或暴露高温。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>开封后：\u003C/strong>按照药品说明，仅允许限定时间和条件下保存，通常冷藏不超过24小时，超过时间须废弃。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>过期药品：\u003C/strong>失效或超过保存期的药品，不可再用。务必交由医疗机构或按照当地药品废弃规定妥善处理，勿随意丢弃。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>运输细节：\u003C/strong>长途运输需专用冷藏箱，并尽量减少颠簸和温度波动。\u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"custom-breastca-cite\">（参考：Herceptin产品手册，Roche，最新版）\u003C/span>\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 08 临床用药经验分享 -->\n  \u003Csection class=\"custom-breastca-section\" style=\"background: linear-gradient(90deg, #f9f9f9 70%, #f3f7fa 100%);padding:32px 24px;border-radius:14px;margin-top:24px;\">\n    \u003Ch2 class=\"custom-breastca-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 📝 案例分享：用药中的关键收获\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cspan class=\"custom-breastca-case\">一位中年女性曲妥珠单抗治疗期间，严格按照方案完成全部8周期，未出现严重不良反应，手术切口愈合良好，恢复顺利。\u003C/span>\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"custom-breastca-case\">有位患者静脉注射曲妥珠单抗后体重稳定，生活质量维持良好，显示规范治疗下安全性理想。\u003C/span>\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 结语 -->\n  \u003Csection class=\"custom-breastca-section\" style=\"background: linear-gradient(90deg, #e8f4fd 30%, #fafcfd 100%);padding:32px 24px;border-radius:14px;margin-top:32px;margin-bottom:24px;\">\n    \u003Ch2 class=\"custom-breastca-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">总结与再提醒 💡\u003C/h2>\n    \u003Cp>\n      曲妥珠单抗作为先进的靶向药物，极大提高了治疗相关乳腺癌患者的依从性和预后，但也要求用药时遵循严格的操作规范。\u003Cbr>\n      最重要的是——务必按医师方案规范操作，关注心脏安全，以及每一次药品的保存和有效期。\u003Cbr>\n      不论用药过程遇到疑问还是感受到异常不适，都要及时与医疗团队沟通。科学合理用药，提高治疗安全性，是每一位患者和家庭都该牢记的核心观念。\n    \u003C/p>\n    \u003Cdiv style=\"font-size:1em;\">\n      \u003Cstrong>主要参考文献：\u003C/strong>\u003Cbr>\n      Baselga, J., Albanell, J., Ruiz, A., et al. (2001). Trastuzumab: mechanism of action and potential for resistance. \u003Ci>Cancer Research, 61\u003C/i>(3), 718-721.\u003Cbr>\n      Slamon, D. J., Leyland-Jones, B., Shak, S., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer. \u003Ci>New England Journal of Medicine, 344\u003C/i>(11), 783-792.\u003Cbr>\n      de Azambuja, E., Procter, M. J., van Veldhuisen, D. J., et al. (2014). Safety and efficacy of trastuzumab. \u003Ci>Annals of Oncology, 25\u003C/i>(6), 1159-1170.\u003Cbr>\n      Pondé, N. F., Aftimos, P., Piccart, M. (2019). Trastuzumab in breast cancer: a tale of two tails. \u003Ci>Nature Reviews Clinical Oncology, 16\u003C/i>(5), 315-316.\u003Cbr>\n      \u003Cspan style=\"font-size:0.97em;color:#888;\">请在需要用药决策时，务必遵照医生或药师的指导，安全第一。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.custom-breastca-guide {\n  font-family: 'Segoe UI', 'Helvetica Neue', Arial, 'PingFang SC', 'Hiragino Sans GB', 'Microsoft Yahei', sans-serif;\n  color: #233039;\n  background: #f8fafb;\n  line-height: 1.8;\n  padding: 0 12px 36px 12px;\n  max-width: 850px;\n  margin: 0 auto;\n  box-sizing: border-box;\n}\n.custom-breastca-title {\n  font-size: 2.3em;\n  font-weight: bold;\n  color: #14608e;\n  text-align: center;\n  margin: 38px 0 24px 0;\n  letter-spacing: 1px;\n}\n.custom-breastca-intro {\n  background: #e9f2fc;\n  border-radius: 13px;\n  padding: 24px 22px 18px 22px;\n  font-size: 1.18em;\n  margin-bottom: 12px;\n  box-shadow: 0 0 5px #eaeaea;\n}\n.custom-breastca-section {\n  margin-bottom: 24px;\n  box-shadow: 0 0 6px #ededed;\n}\n.custom-breastca-h2 {\n  font-size: 1.38em;\n  font-weight: bold;\n  margin-bottom: 14px;\n  padding-left: 2px;\n  color: #206189;\n  letter-spacing: 0.5px;\n  border-left: 0.22em solid #9ad5eb;\n}\n.custom-breastca-section ul {\n  margin: 0 0 14px 0;\n  padding: 0 0 0 1.1em;\n}\n.custom-breastca-section ol {\n  margin: 0.5em 0 0.7em 1.6em;\n  padding-left: 1.25em;\n}\n.custom-breastca-section li {\n  margin-bottom: 0.6em;\n}\n.custom-breastca-cite {\n  color: #6c8a95;\n  font-size: 0.93em;\n  padding-left: 2px;\n  display: block;\n  margin-top: 6px;\n}\n.custom-breastca-section strong {\n  color: #358ac3;\n  font-weight: bold;\n}\n.custom-breastca-case {\n  background: #f5faff;\n  border-left: 5px solid #cdecfa;\n  font-size: 1em;\n  margin: 7px 0 6px 0;\n  padding: 6px 14px;\n  color: #256685;\n  border-radius: 8px;\n  display: block;\n}\n.custom-breastca-section p,\n.custom-breastca-section p,\n.custom-breastca-section span {\n  font-size: 1.06em;\n}\n@media (max-width: 620px) {\n  .custom-breastca-guide {\n    padding: 0 2vw 26px 2vw;\n    max-width: 98vw;\n  }\n  .custom-breastca-title {\n    font-size: 1.4em;\n    margin: 21px 0 12px 0;\n  }\n  .custom-breastca-section {\n    padding: 18px 7px;\n    border-radius: 8px;\n  }\n  .custom-breastca-intro {\n    padding: 13px 7px 8px 7px;\n    font-size: 1em;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"custom-breastca-guide\">\n  \u003Ch1 id=\"material_title\" class=\"custom-breastca-title\" style=\"c",526,"2025-08-29 10:43:30","曲妥珠单抗, HER2阳性乳腺癌, 乳腺癌靶向治疗, 不良反应, 药物相互作用","深入了解曲妥珠单抗在HER2阳性乳腺癌治疗中的应用，包括药理机制、用法剂量及不良反应，帮助患者安全用药，提升医疗效果。","2025-08-31 23:03:09",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]